Comparative Pharmacology
Head-to-head clinical analysis: FINACEA versus PLIAGLIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINACEA versus PLIAGLIS.
FINACEA vs PLIAGLIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelaic acid inhibits microbial protein synthesis, reduces reactive oxygen species production, and modulates keratinocyte and melanocyte function.
Pliaglis is a topical local anesthetic combination of lidocaine and tetracaine. Lidocaine and tetracaine stabilize neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
Apply a pea-sized amount topically twice daily (morning and evening) to affected areas of the face.
Lidocaine 2.5% and prilocaine 2.5% cream: Apply 1 g per 10 cm² of intact skin; cover with occlusive dressing. Maximum dose: 20 g per application for adults weighing ≥70 kg; for <70 kg, max 10 g. Frequency: Single application, minimum 1 hour before procedure, up to 5 hours.
None Documented
None Documented
Not determined clinically due to negligible systemic absorption; after topical application, plasma levels are below quantification limits; no terminal half-life is established.
1.5-2 hours (lidocaine); prolonged in hepatic impairment or heart failure (up to 6-8 hours).
Renal: primarily as unchanged drug (minimal metabolism); approximately 16% of a topical dose is absorbed and excreted renally; fecal excretion is negligible.
Renal: 70% (lidocaine and metabolites); fecal: 10% (primarily unchanged); biliary: 20% (metabolites).
Category C
Category C
Topical Acne Agent / Rosacea Treatment
Topical Acne Agent